AI assistant
Ipsen — Report Publication Announcement 2017
Mar 28, 2017
1449_10-k_2017-03-28_466fe02d-d191-462c-94d6-d18af4b5e062.pdf
Report Publication Announcement
Open in viewerOpens in your device viewer
Regulated information
The Ipsen Group publishes its 2016 Registration Document
Paris (France), 28 March 2017 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that its 2016 Registration Document has been filed with the French "Autorité des Marchés Financiers" (AMF) on 27 March 2017 and registered under the number D.17-0231.
The document is available on the company's website: www.ipsen.com and on the AMF's website: www.amf-france.org. Copies are also available at Ipsen's headquarters – 65 quai Georges Gorse, 92100 Boulogne-Billancourt – France.
The following documents are incorporated into the 2016 Registration Document:
- The Annual Financial Report;
- The Chairman's Report on the preparation and organization of the works of the Board of Directors and internal control procedures and risk management procedures and the corresponding Statutory Auditor's Report;
- The information relating to the fees paid to the Statutory Auditors.
About Ipsen
Ipsen is a global specialty-driven pharmaceutical group with total sales close to €1.6 billion in 2016. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen's commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, neuro-endocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2016, R&D expenditures exceeded €200 million. The Group has more than 4,900 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and are eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trades on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
For further information:
Media
Didier Véron Senior Vice-President, Public Affairs and Communication Tel.: +33 (0)1 58 33 51 16 E-mail: [email protected]
Financial Community Eugenia Litz Vice-President, Investor Relations Tel.: +44 (0) 1753 627721 E-mail: [email protected]
Brigitte Le Guennec Corporate External Communication Manager Tel.: +33 (0)1 58 33 51 17 E-mail : [email protected]
Côme de La Tour du Pin Investor Relations Manager Tel.: +33 (0)1 58 33 53 31 E-mail: [email protected]